User menu

Severe drug-induced liver injury associated with prolonged use of linezolid

Bibliographic reference De Bus, Liesbet ; Depuydt, Pieter ; Libbrecht, Louis ; Vandekerckhove, Linos ; Nollet, Joke ; et. al. Severe drug-induced liver injury associated with prolonged use of linezolid. In: Journal of Medical Toxicology : official journal of the American College of Medical Toxicology, Vol. 6, no.3, p. 322-326 (2010)
Permanent URL
  1. Falagas ME, Vardakas KZ (2008) Benefit–risk assessment of linezolid for serious Gram-positive bacterial infections. Drug Saf 31:753–768
  2. Bishop E, Melvani S, Howden BP, Charles PGP, Grayson ML (2006) Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother 50:1599–1602
  3. Manfredi R (2006) Update on the appropriate use of linezolid in clinical practice. Ther Clin Risk Manag 2:455–464
  4. Vinh DC, Rubinstein E (2009) Linezolid: a review of safety and tolerability. J Infect 59(S1):S59–S74
  5. William ML (2003) Drug-induced hepatotoxicity. N Engl J Med 349:474–485
  6. Abboud G, Kaplowitz N (2007) Drug-induced liver injury. Drug Saf 30:277–294
  7. Lucena MI, Camargo R, Andrade RJ et al (2001) Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 33:123–130
  8. Garcia-Cortés M, Lucena MI, Pachkoria K et al (2008) Evaluation of Naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther 27:780–789
  9. Hussaini SH, Farrington EA (2007) Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf 6:673–684
  10. Fromenty B, Pessayre D (1997) Impaired mitochondrial function in microvesicular steatosis. J Hepatol 26:43–53
  11. Fromenty B, Berson A, Pessayre D (1997) Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation. J Hepatol 26:13–22
  12. Labbe G, Pessayre D, Fromenty B (2008) Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol 22:335–353
  13. McKee EE, Ferguson M, Bentley AT, Marks TA (2006) Inhibition of mammalian mitochondrial protein synthesis. Antimicrob Agents Chemother 50:2042–2049
  14. De Vriese AS, Van Coster A, Smet J et al (2006) Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 42:1111–1117
  15. Garrabou G, Soriano A, Lopez S et al (2007) Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob Agents Chemother 51:962–967
  16. Livermore DM (2000) Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? J Antimicrob Chemother 46:347–350
  17. McKee EE, Ferguson M, Bentley AT et al (2006) Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother 50:2042–2049
  18. Brunt EM (2007) Non alcoholic fatty liver disease. In: MacSween RNM, Burt AD, Portmann BC, Ferrell LD (eds) MacSween’s pathology of the liver, 5th edn. Elsevier Health Sciences, Amsterdam, pp 367–398
  19. Ukleya A, Romano MM (2007) Complications of parenteral nutrition. Gastroenterol Clin N Am 36:23–46
  20. Linden P (2007) Safety profile of meropenem. Drug Saf 30(8):657–668